Moderna stock has fallen over the past four years, but shares got a boost on positive comments about AI. Is MRNA stock a buy ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

Moderna is down 80% from its 52-week high as revenues continue to fall and the new RSV vaccine has performed poorly. Read my ...

Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...

Pharmaceuticals and vector-control programmes have greatly diminished the once-widespread disease, but sustained effort will ...

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

What about an mRNA vaccine for H5N1? There isn't one yet, but several companies—including Moderna, Pfizer and GlaxoSmithKline (in collaboration with CureVac)—are working on such a shot.

In the days since New York Gov. Kathy Hochul declared New York City’s subways had improved in safety, a woman was burned alive, a man was pushed in front of an oncoming train and gangs of ...

Notable medicines subject to price increases include Pfizer’s COVID-19 drug Paxlovid, Bristol Myers Squibb’s CAR-T therapies Abecma and Breyanzi and a clutch of vaccines from Sanofi ...

Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the cash-strapped biotech of up to $220 million in milestones. Pfizer’s decision sent ...